Marshall Wace
LYEL icon

Marshall Wace’s Lyell Immunopharma LYEL Stock Holding History

Marshall Wace’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.98M Buy
148,516
+75,201
+103% +$1.76M ﹤0.01% 1570
2025
Q4 		$2.26M Buy
+73,315
New +$1.64M ﹤0.01% 1520
2025
Q3 		– Sell
-10,580
Closed -$93.5K – 3182
2025
Q2 		$93.5K Buy
+10,580
New +$96.4K ﹤0.01% 2550

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace's LYEL Position: Q1 2026 in Review

Marshall Wace increased its Lyell Immunopharma (LYEL) stake by 103% in Q1 2026, buying an estimated $1.76M and bringing the position to 148,516 shares worth $2.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

Marshall Wace first reported a position in LYEL in Q2 2025 and has held it in 3 quarters since. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Marshall Wace held 148,516 shares of Lyell Immunopharma worth $2.98M as of Q1 2026.
  • Marshall Wace bought 75,201 Lyell Immunopharma shares in Q1 2026, an estimated $1.76M.
  • Lyell Immunopharma made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1570 holding.
  • Marshall Wace first reported a position in Lyell Immunopharma in Q2 2025 and has held it in 3 quarters since.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.